As previously reported, on January 11, the Canadian Agency for Drugs and Technologies in Health (CADTH) posted a discussion paper regarding the proposed framework for a potential pan-Canadian formulary. The pan-Canadian Advisory Panel has posted further information, including respondent feedback and focus group feedback. The Final Report: Building Toward a Potential Pan-Canadian Formulary was released in June, together with summary highlights.
Highlights of the Panel’s recommendations are:
- Six principles for the formulary: universal and integrated; equitable; effective, safe, and high quality; sustainable; efficient and timely; and inclusive, transparent, with fair process.
- A potential pan-Canadian formulary should:
- be a dynamic and living system that involves multiple perspectives
- be aligned with, if not integrated into, other elements of the health system
- be equitable and support a distinction-based approach that promotes self-determination
- incorporate evidence that considers diverse populations, perspectives, and experiences
- be aligned with current evidence
- be sustainable
- adopt systems and process efficiencies, including (i) providing simplified points of access for related products and (ii) exploring a hybrid submission review model.
- Take a staged approach to develop a potential pan-Canadian formulary.
- Build public trust through transparent decision-making.
- Ensure accountability and reason-driven decision-making.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada takes action to address generic drug submission review backlog
Health Canada is not currently meeting its performance standards for the review of some generic drug submissions. On September 1, 2026, Health Canada launched a new webpage, Improving how we review ge...Read More -
PMPRB releases September 2026 NEWSletter
The September NEWSletter also provides information about the PMPRB’s participation in past and future events, as well as NPDUIS research initiative and activities.Read More -
Health Canada provides its quarterly update and PMPRB publishes the 10th edition of the Meds Entry Watch report
On October 15, 2026, Health Canada provided its quarterly update summarizing steps it has taken “to make its regulatory processes more modern and efficient, while maintaining high standards for safety...Read More
